Lu AG13909

Phase 2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cushing's Disease

Conditions

Cushing's Disease

Trial Timeline

Jun 19, 2024 → Nov 30, 2027

NCT ID

NCT06471829

About Lu AG13909

Lu AG13909 is a phase 2 stage product being developed by Lundbeck for Cushing's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06471829. Target conditions include Cushing's Disease.

What happened to similar drugs?

2 of 10 similar drugs in Cushing's Disease were approved

Approved (2) Terminated (1) Active (7)

✅Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved

✅Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved

🔄pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3

🔄Pasireotide sub-cutaneousNovartisPhase 3

🔄osilodrostat + osilodrostat PlaceboNovartisPhase 3

🔄PasireotideNovartisPhase 3

🔄mifepristoneCorcept TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06471829	Phase 2	Recruiting	Jun 19, 2024	Nov 30, 2027	Cushing's Disease
NCT05669950	Phase 1/2	Recruiting	Dec 19, 2022	Dec 31, 2027	Congenital Adrenal Hyperplasia

Competing Products

18 competing products in Cushing's Disease

See all competitors

Product	Company	Stage	Hype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisolone	AstraZeneca	Phase 2	35
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mg	Novartis	Phase 3	40
Pasireotide sub-cutaneous	Novartis	Phase 3	40
osilodrostat + osilodrostat Placebo	Novartis	Phase 3	40
Osilodrostat	Novartis	Phase 2	35
Pasireotide	Novartis	Phase 3	40
Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin	Novartis	Approved	43
SOM230 s.c.	Novartis	Phase 2	35
Osilodrostat	Recordati	Pre-clinical	23
Pasireotide + Cabergoline + Pasireotide LAR	Recordati	Approved	40
osilodrostat	Recordati	Phase 2	32
Osilodrostat	Recordati	Pre-clinical	27
mifepristone	Corcept Therapeutics	Phase 3	37
CORT125134	Corcept Therapeutics	Phase 2	32
Cushing's syndrome confirmation	Corcept Therapeutics	Pre-clinical	15
Mifepristone	Corcept Therapeutics	Phase 3	37
mifepristone	Corcept Therapeutics	Phase 3	37
mifepristone	Corcept Therapeutics	Phase 3	29